CLINICAL TRIALS PROFILE FOR PULMICORT FLEXHALER
✉ Email this page to a colleague
All Clinical Trials for pulmicort flexhaler
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00702325 ↗ | Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans | Completed | AstraZeneca | Phase 4 | 2008-06-01 | To compare the efficacy of SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily (bid) to that of budesonide inhalation powder DPI 180 μg x 2 inhalations bid, in African American(self-reported) subjects with inhaled corticosteroid (ICS) dependent asthma. |
NCT01218399 ↗ | Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations | Completed | AstraZeneca | N/A | 2009-09-01 | This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with Stanford staff. We hypothesize that the budesonide/formoterol combination improves the efficacy of budesonide alone. |
NCT01218399 ↗ | Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations | Completed | Stanford University | N/A | 2009-09-01 | This is an investigator-initiated study in which Dr. Nadeau wrote the protocol and received funding from an Astra Zeneca grant to direct, perform, and monitor the study on her own with Stanford staff. We hypothesize that the budesonide/formoterol combination improves the efficacy of budesonide alone. |
NCT01219738 ↗ | Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide | Completed | AstraZeneca | N/A | 2008-07-01 | Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation. One of these non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g. locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists (e.g. inhaled beta-adrenergic agonists). |
NCT01219738 ↗ | Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide | Completed | University of Miami | N/A | 2008-07-01 | Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation. One of these non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g. locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists (e.g. inhaled beta-adrenergic agonists). |
NCT01520688 ↗ | Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth | Completed | West Penn Allegheny Health System | Phase 4 | 2012-02-01 | Children with mild persistent asthma that have asthma symptoms once or twice a week and use a daily controller, while children with mild intermittent asthma rarely have asthma symptoms and do not use a daily controller. Inhaled corticosteroids are the standard treatment for mild peristent asthma. The purpose of this study is to measure children rate of growth while on different inhaled corticosteroids. |
NCT02357277 ↗ | The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton | Withdrawn | Columbia University | Phase 4 | 2015-03-01 | There are over 10 million individuals with asthma using inhaled glucocorticoids (IGCs) in the United States. While oral GCs are recognized to have destructive skeletal effects, far less is known about the effects of IGCs. This gap in our knowledge is of critical importance, not only because of the prevalence, chronic nature and long duration of IGC use, but also because several studies have found that patients using IGCs are at increased risk of fracture. Fracture risk is greatest in postmenopausal (PM) women, in whom IGCs may augment negative effects of estrogen loss and aging. The investigators hypothesize that initiation of IGCs in IGC naïve PM women will lead to decreased bone formation and uncoupling of bone turnover, a potential mechanism for the effect of IGCs on the skeleton. To test our hypothesis, the investigators will perform a randomized, controlled 4 week study of the acute effects of commonly used doses of budesonide (360 or 720 mcg) on bone turnover and circulating osteoblast precursors in 60 treatment naïve, non-asthmatic, PM women. These studies are of high clinical significance because there are currently no guidelines regarding screening, prevention or treatment for osteoporosis in patients using IGCs, nor is IGC use taken into account when calculating fracture risk in PM women, the group at highest risk of fracture. High quality evidence for low volumetric bone mineral density (BMD) and abnormal bone quality in PM women using IGCs has the potential to change clinical practice by supporting specific interventions to prevent bone loss and fractures. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for pulmicort flexhaler
Condition Name
Clinical Trial Locations for pulmicort flexhaler
Trials by Country
Clinical Trial Progress for pulmicort flexhaler
Clinical Trial Phase
Clinical Trial Sponsors for pulmicort flexhaler
Sponsor Name